A Phase II study of MAOA inhibitor plus docetaxel in patients receiving and progressing on docetaxel therapy
The purpose of this study is to learn if the study drug (phenelzine) can restore chemotherapy sensitivity in patients who are beginning to progress on standard docetaxel chemotherapy.
* Subjects will have confirmed andenocarcinoma of the prostate that has spread outside the prostate and is no longer responding to hormone therapy.
*Subject must have evidence of progression during (while on therapy or within 45 days of the last dose administered) docetaxel therapy
*Subject must be willing to undergo a baseline tumor biopsy
*Subject must enroll in the study within 3 months of last docetaxel dose
18 - 100
Healthy Volunteers Needed
Duration of Participation
6-12 months of active treatment
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Wayne D. Kuni and Joan E. Kuni Foundation & DHHS NIH National Cancer Institute